Leadingpharm was established in 2005 with registered capital of nearly 100 million yuan and was listed on the Shanghai Stock Exchange in 2015 (stock code: 600222). It is a high-tech enterprise providing pharmacy pre-clinical research, clinical CRO and CDMO services to the whole world. It has been rated as "China’s Top 10 Pharmaceutical R&D Enterprises "for many years (ranked first in 2019).
From the beginning of its establishment, Leadingpharm took "We make China a world-class player in pharmaceutical technology and production process" as the enterprise vision, hoping to let more Chinese people can use safe medicine.Until now, Leadingpharm has built cooperation with over 500 upstream and downstream enterprises. More than 400 pharmaceutical research and development projects and more than 500 clinical research projects have been undertaken, more than 200 patents have been applied for, and nearly 100 patents have been licensed .
Leadingpharm is headquartered in Beijing Zhongguancun High-tech Park with 10000㎡ R&D laboratories. There are New Drug Screening and Testing Platform, Drug Evaluation Platform (animal room, certified by GLP, AAALAC, CNAS), Large Molecule Pilot and Large-scale Production Platform, Small Molecule CMC Research and Production Platform, Cell Technology Platform and Clinical CRO Platform in Lifezhengzhou. The six platforms comply with international standards (FDA, EMA and NMPAGMP), forming Leadingpharm CXO Whole Industry Chain Service System. As a combination of imitation and creation, Leadingpharm is driven by dual engines and can provide customers with diversified services throughout the pharmaceutical research and development.